Consider the high-conviction biotech picks Spruce Biosciences (SPRB), Abivax (ABVX), and Sarepta (SRPT) for potential long-term investment. A strong bearish view is held on Olema Pharmaceuticals (OLMA), which is being actively shorted with a potential daily price target of $12. For a shorter-term trade, Palantir (PLTR) is favored for momentum trading on the long side. Leading up to its earnings report, NVIDIA (NVDA) is expected to beat estimates and raise future guidance. Lastly, despite its partnerships, IonQ (IONQ) is identified as a high-conviction shorting opportunity based on skepticism of its valuation.

Olema Pharmaceuticals (OLMA)

• The speaker is actively shorting the stock, indicating a strong belief that its price will go down.
• He mentions a potential price target of $12 for the day of the podcast.
• The speaker believes that recent positive news from competitor Roche in the breast cancer space is not beneficial for OLMA.
• He describes the market for CERDs (Selective Estrogen Receptor Degraders), which is OLMA's focus, as "very crowded" and "competitive," suggesting it will be difficult for the company to stand out.
• The sentiment is extremely bearish, with the speaker calling the stock "dog poo poo" and joking that its ticker can be reversed to spell "LMAO."

Takeaways

• The speaker has a strong bearish (negative) conviction on OLMA.
• This is presented as a high-risk short-selling opportunity based on the view that the company is in a highly competitive field and that its stock is overvalued.
• Investors might consider this strong negative sentiment as a reason to avoid the stock or conduct deep due diligence on the competitive landscape for breast cancer treatments.

IonQ (IONQ)

• The transcript presents two completely opposite views on IonQ.
• The Speaker's View (Bearish):
  • He expresses extreme negative sentiment, stating "All my homies hate IonQ" and calling it a "real dog shit company."
  • He is actively betting against the stock, mentioning he wants to "buy more IonQ puts" and that the stock's rally is "killing me."
  • He identifies it as a "really good shorting opportunity."
• IonQ CEO's View (Bullish):
  • The transcript includes congressional testimony from IonQ's CEO, Niccolo DeMasi, who presents a very positive case.
  • He claims IonQ is the world's leading pure-play quantum computing company with a "five-year lead" over China.
  • He highlights major partnerships with companies like AstraZeneca, Amazon Web Services (AWS), and NVIDIA for projects like accelerating drug design.
  • He projects that the economic impact of quantum technologies will be in the "trillions of dollars."

Takeaways

• IONQ is a highly controversial and volatile stock with powerful arguments from both bulls and bears.
• The Bearish Case: The speaker believes the company is fundamentally flawed and overhyped, making it a candidate for a short sale.
• The Bullish Case: The company's leadership presents it as a revolutionary leader in a world-changing industry with massive long-term potential.
• This is a classic high-risk, high-reward investment. Investors should be aware of the extreme volatility and the deeply divided opinions on the company's future.

NVIDIA (NVDA)

• The speaker has a generally bullish outlook on NVIDIA, expecting the company to "beating Rays" (beat earnings estimates and raise future guidance) in its upcoming report.
• A minor risk factor is mentioned: Google's new AI model, Gemini, was trained on Google's proprietary TPUs, not NVIDIA's GPUs. This highlights the growing competition in the AI chip space.
• On the positive side, NVIDIA is mentioned as a key partner for companies in emerging technologies, such as the quantum computing firm IonQ.

Takeaways

• The near-term sentiment is positive, with an expectation of a strong earnings report that could act as a catalyst for the stock price.
• Investors should monitor the competitive landscape, particularly how much market share other chip designers like Google can take in the AI training market.
• NVIDIA's role as a key supplier to a wide range of innovative companies remains a core part of its investment thesis.

Biotech Conviction Picks (SPRB, ABVX, SRPT)

• The speaker explicitly names three biotech stocks that he is "over the moon about":
  • Spruce Biosciences (SPRB)
  • Abivax (ABVX)
  • Sarepta (SRPT)
• He confirms he is "still long" SPRB, indicating an ongoing investment.

Takeaways

• These three companies are the speaker's high-conviction bullish picks in the biotech sector.
• While detailed reasons are not provided in this transcript, the strong endorsement suggests these are names that investors interested in biotech may want to research further.

Palantir (PLTR)

• The speaker states that he likes Palantir (PLTR) specifically "for trading on the long side."
• He notes that the stock has "always been pretty good to me," implying he has had past success trading it.

Takeaways

• This is a bullish but tactical view. The speaker sees PLTR as a good stock for short-to-medium-term trades rather than a long-term, buy-and-hold investment.
• Investors might watch PLTR for favorable entry points to trade its momentum, based on the speaker's experience.

AI & US Robotics (Investment Theme)

• AI Software: The speaker believes that no single company will "win the AI war." He expects the market to be shared by current leaders like OpenAI (Private), Google (GOOGL), and Anthropic (Private), as well as new companies that emerge.
• US Robotics & Manufacturing: Testimony from the CEO of StandardBots (Private) highlights a major theme: rebuilding America's manufacturing strength to compete with China.
  • He argues for a national strategy to support US robotics, potentially including tariffs on Chinese robots.
  • He notes that US manufacturers currently face a significant cost disadvantage compared to Chinese suppliers.

Takeaways

• For AI, a diversified approach of investing in a basket of leading companies may be more prudent than betting on a single winner.
• "Reshoring" and strengthening US manufacturing is a major investment theme. This could create significant growth opportunities for US-based robotics, automation, and industrial companies, especially if the government enacts supportive policies.

Other Bearish Mentions

• The speaker expresses negative opinions on several other stocks:
  • Arvinus (ARVN): Believes its recent price increase is unjustified as it operates in a "very competitive space."
  • IFRX (InflaRx): He bought the stock but now calls it a "fucking dog," using it as an example of when to cut your losses.
  • BTQ: Calls the company "stupid" and its news "fugazi" (fake), identifying it as a shorting opportunity.

Takeaways

• These stocks are flagged with strong bearish sentiment and should be approached with caution.
• The comment on IFRX provides a general investment lesson: it's important to have a strategy for selling losing positions ("put a dog to sleep") to manage risk.